System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Aurore Perrot is an expert in Hematology at Oncopole Claudius Regaud (France). As of October 2026, ScienceLeadR ranks Aurore Perrot in the top 1% of experts worldwide for Multiple Myeloma, Hemostatic Disorders and Paraproteinemias. Aurore Perrot has authored 421 publications, the most recent in 2026, and is an investigator in 76 clinical trials, 37 of them ongoing. SLR score: 2,367 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Aurore Perrot Oncopole Claudius Regaud France
2 367 ScienceLeadR Reputation 2367

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Immunology - Cardiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2009 - 2026
Source: PubMed

Cancer Research Center of Toulouse

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 421

Citations

Citations: 9 007 1st author: 37 Last author: 27 Unique author: 3

Main journals

Blood 125
CL LYMPH MYELOM LEUK 62
Hemasphere 25
J Clin Oncol 25
Br J Haematol 18

Best Journals

J Clin Oncol 23
N Engl J Med 10
Lancet Oncol 5

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy.
PMID 42897348 — genes, epigenomics, molecular biology, dexamethasone, multiple myeloma, neoplasm, residual, therapeutics		Nat Med Top journal20260
Supportive Care in Multiple Myeloma: Evidence-Based Recommendations From the Intergroupe Francophone du Myélome (IFM).
PMID 42864252 — cells, quality of life, antibodies, lymphoma, multiple myeloma, therapeutics, antibodies, bispecific, receptors, antigen, t-cell		Clin Lymphoma Myeloma Leuk20260
Longitudinal assessments of MRD in high-risk newly diagnosed transplant-ineligible multiple myeloma in the BENEFIT study (IFM2020-05).
PMID 42835780 — multiple myeloma, transplants		Hemasphere20260
Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS.
PMID 42789828 — safety, dexamethasone, bortezomib, multiple myeloma, lenalidomide, transplants		J Clin Oncol Top journal20260
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.
PMID 42637879 — dexamethasone, leukemia, survival analysis, multiple myeloma, lenalidomide, transplants, therapeutics		Leukemia20260

Clinical Studies 76

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

Phase 3 42
Phase 2 16
N/A 7
Phase 1/Phase 2 5
Phase 1 4
Phase 2/Phase 3 2

By status:

Active not recruiting 26
Completed 20
Recruiting 17
Unknown 6
Not yet recruiting 4
Terminated 3

By type:

Interventional 71
Observational 5

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 1
multicentric5to9 2
multicentricup10 68

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

37 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 3 Randomized Study Comparing JNJ 79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
2025-523815-12-00 — multiple myeloma, lenalidomide, therapeutics		Phase 3Not yet recruiting2026
Cevostamab in Combination with Pomalidomide and Dexamethasone Versus Standard of Care in Patients with Previously Treated Multiple Myeloma
2025-524028-23-00 — safety, dexamethasone, multiple myeloma, therapeutics		Phase 3Not yet recruiting2026
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal DR) versus Daratumumab SC Lenalidomide and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy
2023-503442-30-00 — cells, microscopy, electron, scanning transmission, dexamethasone, stem cells, multiple myeloma, lenalidomide, transplants, therapeutics		Phase 3Active not recruiting2022
MagnetisMM 6 A Phase 3 Study of Elranatamab (PF 06863135) Daratumumab Lenalidomide Versus Daratumumab Bortezomib Lenalidomide Dexamethasone in Transplant Ineligible Participants With Newly Diagnosed Multiple Myeloma
2024-514139-50-00 — safety, dexamethasone, bortezomib, multiple myeloma, lenalidomide, transplants		Phase 3Recruiting2022
IFM2024 06 A multi center open label phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as post transplantation maintenance therapy in patients with newly diagnosed myeloma
2024-517325-43-00 — multiple chronic conditions, maintenance, multiple myeloma, lenalidomide, therapeutics, transplantation		Phase 2Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS